Ovid.com  |  Login  |  Technical Support  

Advanced Search
Ovid News
Learn about Ovid’s new research content and products.
Ovid Events
Check out where Ovid is across the globe at industry conferences and events worldwide.
Are you affiliated with a leading medical or academic institution?
If so, send your librarian an email recommending titles you’ve found valuable for research at your institution.
Home About Products & Services Contact Us btn_contact1
Clinical Chemistry and Laboratory Medicine

February 2007, 45:2 > Renal impairment compromises the...
< Previous  |   Next >
Fulltext  |  PDF (69 K)
Renal impairment compromises the use of total homocysteine and methylmalonic acid but not total vitamin B12 and holotranscobalamin in screening for vitamin B12 deficiency in the aged.

Original Article

Clinical Chemistry & Laboratory Medicine. 45(2):197-201, February 2007.
Loikas, Saila 1,*; Koskinen, Pertti 1; Irjala, Kerttu 1,2; Lopponen, Minna 3,4; Isoaho, Raimo 3,5; Kivela, Sirkka-Liisa 3,6,7; Pelliniemi, Tarja-Terttu 1

Background: Vitamin B12 deficiency and renal impairment are common in the aged, and therefore the screening test for vitamin B12 deficiency should not be affected by renal function. Renal impairment has been associated with increased concentrations of plasma total homocysteine and methylmalonic acid, as well as increased total vitamin B12 and holotranscobalamin concentrations.

Methods: The effect of renal impairment on vitamin B12-related biochemical variables was assessed in 1011 aged subjects.

Results: Renal function as indicated by serum cystatin C correlated strongly with plasma total homocysteine (rs=0.53, p<0.001) and serum methylmalonic acid (rs=0.27, p<0.001), but not with serum total vitamin B12 (rs=-0.04, p=0.227) or holotranscobalamin (rs=-0.01, p=0.817).

Conclusions: Either total vitamin B12 or holotransco-balamin rather than homocysteine or methylmalonic acid should be used when screening an aged population prone to renal impairment.

Copyright (C) 2007 Walter de Gruyter